Skip to main content
NVDA-4.42%AAPL+0.54%GOOGL-3.46%MSFT-1.99%AMZN-4.86%TSM-4.72%SPCX-9.29%META-7.81%AVGO-4.05%TSLA-2.69%LLY+2.82%BRK-B+1.90%MU-5.70%SKHY-7.12%WMT+2.38%JPM-0.04%AMD-7.96%V+1.14%XOM-0.37%JNJ+4.29%ASMLa-4.74%MA+1.17%ABBV-0.11%INTC-7.54%COST+1.49%CVX-0.18%0700.HK-2.89%1398.HK-1.34%CSCO-2.17%KO+2.38%PG+6.06%ORCL-3.93%UNH+1.67%BAC+0.46%1816.HK-0.22%3988.HK-1.80%HD+3.60%CAT-5.30%0005.HK-1.23%HSBA.L-2.45%PM+1.55%AP2d-6.79%0857.HK-0.82%AMAT-7.36%1288.HK-0.30%GE-1.71%0939.HK-0.61%NVS+1.54%LRCX-11.60%MS-1.94%PLNJPY-1.39%EURAUD-1.16%EURCAD-1.12%AUDUSD+1.01%USDCAD-0.95%EURJPY-0.89%GBPZAR+0.88%USDZAR+0.83%SGDJPY-0.83%USDTHB+0.83%USDJPY-0.77%EURZAR+0.72%EURGBP-0.70%EURNZD-0.70%CHFSEK+0.70%EURCHF-0.58%AUDCHF+0.57%NZDUSD+0.56%USDPLN+0.56%GBPUSD+0.55%CADCHF+0.54%AUDNOK-0.53%NOKJPY-0.48%CHFSGD+0.48%EURNOK-0.47%GBPAUD-0.46%AUDNZD+0.46%EURPLN+0.45%USDCHF-0.44%GBPCAD-0.43%GBPTRY+0.41%NZDCAD-0.41%CHFJPY-0.35%USDNOK-0.35%GBPHKD+0.32%NZDSGD-0.31%AUDJPY+0.29%GBPMXN-0.28%USDMXN+0.23%EURHKD-0.22%CADJPY+0.22%NZDJPY-0.22%USDSEK+0.21%GBPJPY-0.21%USDTRY+0.21%USDCNH-0.19%AUDSGD-0.18%USDILS+0.16%EURUSD-0.15%USDHKD-0.13%CHFNOK+0.12%EURSGD-0.11%NZDCHF+0.11%EURCNH-0.11%EURSEK+0.11%GBPCHF+0.11%USDDKK+0.10%NZDMXN-0.09%AUDDKK-0.08%AUDCAD+0.05%EURCZK+0.05%GBPSGD+0.04%USDCOP-0.04%GBPNZD-0.03%EURDKK-0.01%USDSGD0.00%XAGUSD-5.65%GAGUSD-5.65%XPTUSD-3.67%HG1-2.80%GAUUSD-2.62%XAUUSD-2.62%UKOIL+2.49%USOIL+1.57%XNGUSD-0.02%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-3.36%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.69%ZECUSDT-8.22%DOGEUSD+14.39%XMRUSDT-1.93%LINKUSD+14.52%XLMUSD-4.41%BCHUSDT-4.16%LTCUSD+8.69%UNIUSD-6.08%SUIUSD-5.04%HBARUSDT-5.51%TONUSD+26.39%TAOUSDT-5.46%AAVEUSD-5.89%DOTUSDT-2.43%ICPUSDT-5.94%WLDUSDT-5.15%ONDOUSDT-7.00%ARBUSDT-4.07%JUPUSDT-5.78%ATOMUSDT-2.63%INJUSDT-6.78%STXUSDT-10.57%TIAUSDT-6.23%FETUSDT-6.21%PYTHUSDT-6.75%SEIUSDT-7.66%IMXUSDT-7.27%GRTUSDT-5.64%OPUSDT-7.98%WIFUSDT-6.52%IOTAUSDT-4.44%AXSUSDT-5.36%POLUSDT-4.72%FARTCOINUSDT-5.28%EOSUSDT-0.66%DYDXUSDT-5.96%GALAUSDT-5.61%ORDIUSDT-2.97%RONINUSDT-3.56%NOTUSDT-4.94%NVDA-4.42%AAPL+0.54%GOOGL-3.46%MSFT-1.99%AMZN-4.86%TSM-4.72%SPCX-9.29%META-7.81%AVGO-4.05%TSLA-2.69%LLY+2.82%BRK-B+1.90%MU-5.70%SKHY-7.12%WMT+2.38%JPM-0.04%AMD-7.96%V+1.14%XOM-0.37%JNJ+4.29%ASMLa-4.74%MA+1.17%ABBV-0.11%INTC-7.54%COST+1.49%CVX-0.18%0700.HK-2.89%1398.HK-1.34%CSCO-2.17%KO+2.38%PG+6.06%ORCL-3.93%UNH+1.67%BAC+0.46%1816.HK-0.22%3988.HK-1.80%HD+3.60%CAT-5.30%0005.HK-1.23%HSBA.L-2.45%PM+1.55%AP2d-6.79%0857.HK-0.82%AMAT-7.36%1288.HK-0.30%GE-1.71%0939.HK-0.61%NVS+1.54%LRCX-11.60%MS-1.94%PLNJPY-1.39%EURAUD-1.16%EURCAD-1.12%AUDUSD+1.01%USDCAD-0.95%EURJPY-0.89%GBPZAR+0.88%USDZAR+0.83%SGDJPY-0.83%USDTHB+0.83%USDJPY-0.77%EURZAR+0.72%EURGBP-0.70%EURNZD-0.70%CHFSEK+0.70%EURCHF-0.58%AUDCHF+0.57%NZDUSD+0.56%USDPLN+0.56%GBPUSD+0.55%CADCHF+0.54%AUDNOK-0.53%NOKJPY-0.48%CHFSGD+0.48%EURNOK-0.47%GBPAUD-0.46%AUDNZD+0.46%EURPLN+0.45%USDCHF-0.44%GBPCAD-0.43%GBPTRY+0.41%NZDCAD-0.41%CHFJPY-0.35%USDNOK-0.35%GBPHKD+0.32%NZDSGD-0.31%AUDJPY+0.29%GBPMXN-0.28%USDMXN+0.23%EURHKD-0.22%CADJPY+0.22%NZDJPY-0.22%USDSEK+0.21%GBPJPY-0.21%USDTRY+0.21%USDCNH-0.19%AUDSGD-0.18%USDILS+0.16%EURUSD-0.15%USDHKD-0.13%CHFNOK+0.12%EURSGD-0.11%NZDCHF+0.11%EURCNH-0.11%EURSEK+0.11%GBPCHF+0.11%USDDKK+0.10%NZDMXN-0.09%AUDDKK-0.08%AUDCAD+0.05%EURCZK+0.05%GBPSGD+0.04%USDCOP-0.04%GBPNZD-0.03%EURDKK-0.01%USDSGD0.00%XAGUSD-5.65%GAGUSD-5.65%XPTUSD-3.67%HG1-2.80%GAUUSD-2.62%XAUUSD-2.62%UKOIL+2.49%USOIL+1.57%XNGUSD-0.02%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-3.36%ETHUSD+16.36%USDTUSD-0.02%XRPUSD+9.91%SOLUSD+10.75%TRXUSDT-0.69%ZECUSDT-8.22%DOGEUSD+14.39%XMRUSDT-1.93%LINKUSD+14.52%XLMUSD-4.41%BCHUSDT-4.16%LTCUSD+8.69%UNIUSD-6.08%SUIUSD-5.04%HBARUSDT-5.51%TONUSD+26.39%TAOUSDT-5.46%AAVEUSD-5.89%DOTUSDT-2.43%ICPUSDT-5.94%WLDUSDT-5.15%ONDOUSDT-7.00%ARBUSDT-4.07%JUPUSDT-5.78%ATOMUSDT-2.63%INJUSDT-6.78%STXUSDT-10.57%TIAUSDT-6.23%FETUSDT-6.21%PYTHUSDT-6.75%SEIUSDT-7.66%IMXUSDT-7.27%GRTUSDT-5.64%OPUSDT-7.98%WIFUSDT-6.52%IOTAUSDT-4.44%AXSUSDT-5.36%POLUSDT-4.72%FARTCOINUSDT-5.28%EOSUSDT-0.66%DYDXUSDT-5.96%GALAUSDT-5.61%ORDIUSDT-2.97%RONINUSDT-3.56%NOTUSDT-4.94%
AT

Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ • Healthcare

$11.07
+$0.08 (+0.8%)
Market open

Last close at October 21, 2026 at 20:00 UTC

Open$11.11
Previous Close$11.07
Day Range$11.05 - $11.34
Avg. Volume (3M)715.4K
Market Cap$306.1M
52 Week Range
$5.5$17.96
Next EarningsIn 18 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$2.9M100%
Gross Profitminus cost of goods$2.9M100%

Fundamentals & Financials

Revenue (TTM)
$23.8M
Net Income (TTM)
-$93.2M
EPS (TTM)
-$3.33
ROA (TTM)
-41.58%
Current Ratio
5.88
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-12.0%Q1 2026-$1.03
+7.4%Q2 2026-$0.95
+15.7%Q3 2026-$0.84
Next

Nov 9

in 18 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +15.7%

Arcturus Therapeutics’ fiscal second quarter of 2026 beat EPS expectations while revenue missed consensus, with results reported Aug. 6 as revenue fell about 88% year over year to roughly $3.0 million. Revenue of about $3.0 million missed the $3.1 million consensus by about 5%, while gross profit also came in at about $3.0 million, leaving gross margin near 100% and operating margin around -863% as the company posted an operating loss of roughly $25.5 million. Net income fell about 159% to a loss of roughly $23.8 million from $9.2 million a year ago, and EPS of -$0.84 beat the -$1.00 estimate by about 16% even as it was down about 147% from -$0.34 a year ago. Operating cash flow was negative $39.4 million. Consensus for the next period calls for EPS of -$0.92 on revenue of $4.1 million.

Next report — what to expect

Arcturus Therapeutics Holdings Inc. (ARCT) reports on November 9, 2026. The next-period consensus calls for EPS of -$0.68 on revenue of $8.0 million. For trailing context, revenue fell -87.9% year over year last quarter. Arcturus has beaten EPS in 6 of 8 most recent quarters.

View full earnings history

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc. develops RNA-based medicines as a NASDAQ-listed biotechnology company in healthcare, with programs covering infectious-disease vaccines and treatments for rare liver and respiratory conditions. The company recorded $67.2 million in FY2025 revenue and centers its platform on the LUNAR development portfolio.

Name
Arcturus Therapeutics Holdings Inc.
CEO
Joseph E. Payne
Website
arcturusrx.com
Industry
Healthcare
Year Founded
2013
Employees
109

Today's Snapshot

AI-generated

ARCT is trading 4.7% lower at 10.55, against a firmer sector. Arcturus Therapeutics unveiled LUNAR 2.0, a lipid drug-delivery system.

Trading Volume

Below 10d avg (548.4K)

164K

vs S&P 500 Today

Strong Underperformance

-3.74%

Updated: October 22, 2026 at 16:42 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
ARCT shows short-term weakness despite some deeply oversold oscillators; stochastic and Williams readings signal buying interest while RSI and MACD remain weak and momentum is negative. The stock sits beneath short- and medium-term averages but remains above longer-term references including the 100- and 200-day levels, producing a mixed timeframe picture. Trend strength is muted with ADX under 17, while ATR is elevated at roughly a 10% range, pointing to heightened intraday swings. The pivot near $11.15 also lies above the market, reinforcing short-term resistance. Technical takeaway: Sell — short-term weakness amid low trend strength and elevated volatility.
All signals
  • EMA (5 indicators)$9.80 - $12.16
    Sell
  • RSI (14)38.44
    Neutral
  • Stochastic %K (14, 3, 3)12.77
    Buy
  • MACD Level (12, 26)-0.80
    Sell

Peers & Related Assets

VIRVir Biotechnology, Inc.
$10.57-1.6%
NVAXNovavax, Inc.
$11.01-3.7%
ABUSArbutus Biopharma Corp
$4.18-3.5%
AVIRAtea Pharmaceuticals, Inc.
$4.08-8.7%
RCKTRocket Pharmaceuticals, Inc.
$2.2-6.0%
SLNSilence Therapeutics plc
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.